U.S. Food and Drug Administration staff questioned the benefits of Genta Inc.'s experimental drug Genasense on Tuesday for patients with a type of blood cancer, and the company’s stock fell more than 35 percent. Shares of Genta were halted on Wednesday pending the outcome of a Food and Drug Administration advisory panel hearing on its oncology drug candidate Genasense.
